Reporting owner · CIK 0001780088

Ticho Barry

SEC Form 4 history across 1 companies, 7 transactions and 3 filings.

CMOCHIEF MEDICAL OFFICERStoke Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 5 sales

Available history · Aug 14, 2026 – Oct 01, 2026

Filings3Form 4 records
Buying$00 purchases
Selling$350.2K5 sales
Net value−$350.2KBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Ticho Barry transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
STOKStoke Therapeutics, Inc.
Ticho BarryCMOS · sale10b5-1 detectedSEC filing ↗-$27.4kView disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOS · sale10b5-1 detectedSEC filing ↗-$49.6kView disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOS · sale10b5-1 detectedSEC filing ↗-$120kView disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOM · exerciseDerivative securitySEC filing ↗$0View disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOS · saleSEC filing ↗-$7.85kView disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOS · saleSEC filing ↗-$144kView disclosure →
STOKStoke Therapeutics, Inc.
Ticho BarryCMOM · exerciseSEC filing ↗$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

sale at Stoke Therapeutics, Inc. on Oct 01, 2026 valued at $27,494.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Stoke Therapeutics, Inc. on Oct 01, 2026 valued at $27,494.

Review SEC filing

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202602$0.00$152,689.86-$152,689.86
Sep 202602$0.00$170,060.88-$170,060.88
Oct 202601$0.00$27,493.53-$27,493.53

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$70K
Median P/S size$49.7K
Direct7
Indirect0
Oct 01, 2026sale

Associated companies

Companies in the disclosed reporting history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in available history

A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

6 observations · Aug 14, 2026 – Oct 1, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 1, 202619,059 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 14, 202630,422Aug 19, 2026View transaction
Aug 18, 202625,897Aug 19, 2026View transaction
Aug 18, 202625,655Aug 19, 2026View transaction
Sep 1, 202621,710Sep 3, 2026View transaction
Sep 1, 202620,110Sep 3, 2026View transaction
Oct 1, 202619,059Oct 2, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Ticho Barry Insider Activity FAQ

SEC Form 4 context

Who is Ticho Barry?

Ticho Barry is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001780088.

Which companies has Ticho Barry reported transactions for?

Stoke Therapeutics, Inc.

When was Ticho Barry's latest insider buy?

No open-market insider purchase is available for this period.

When was Ticho Barry's latest insider sale?

sale at Stoke Therapeutics, Inc. on Oct 01, 2026 valued at $27,494.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.